vicente valero
vicente valero
Unknown affiliation
Verified email at
Cited by
Cited by
Adjuvant trastuzumab in HER2-positive breast cancer
D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, M Press, ...
New England journal of medicine 365 (14), 1273-1283, 2011
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
WF Symmans, F Peintinger, C Hatzis, R Rajan, H Kuerer, V Valero, ...
Journal of Clinical Oncology 25 (28), 4414-4422, 2007
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
K Stemke-Hale, AM Gonzalez-Angulo, A Lluch, RM Neve, WL Kuo, ...
Cancer research 68 (15), 6084-6091, 2008
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics
BT Hennessy, AM Gonzalez-Angulo, K Stemke-Hale, MZ Gilcrease, ...
Cancer research 69 (10), 4116-4124, 2009
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
V Serra, B Markman, M Scaltriti, PJA Eichhorn, V Valero, M Guzman, ...
Cancer research 68 (19), 8022-8030, 2008
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
KR Hess, K Anderson, WF Symmans, V Valero, N Ibrahim, JA Mejia, ...
Journal of clinical oncology 24 (26), 4236-4244, 2006
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment
MS Ewer, MT Vooletich, JB Durand, ML Woods, JR Davis, V Valero, ...
Journal of Clinical Oncology 23 (31), 7820-7826, 2005
Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
AD Seidman, MN Fornier, FJ Esteva, L Tan, S Kaptain, A Bach, ...
Journal of Clinical Oncology 19 (10), 2587-2595, 2001
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2–overexpressing metastatic breast cancer
FJ Esteva, V Valero, D Booser, LT Guerra, JL Murray, L Pusztai, ...
Journal of Clinical Oncology 20 (7), 1800-1808, 2002
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular SubtypesDifferential Response to Chemotherapy by TNBC Subtype
H Masuda, KA Baggerly, Y Wang, Y Zhang, AM Gonzalez-Angulo, ...
Clinical cancer research 19 (19), 5533-5540, 2013
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
V Guarneri, K Broglio, SW Kau, M Cristofanilli, AU Buzdar, V Valero, ...
Journal of clinical oncology 24 (7), 1037-1044, 2006
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer
DP Atchley, CT Albarracin, A Lopez, V Valero, CI Amos, ...
Journal of Clinical Oncology 26 (26), 4282, 2008
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
M Ayers, WF Symmans, J Stec, AI Damokosh, E Clark, K Hess, M Lecocke, ...
Journal of clinical oncology 22 (12), 2284-2293, 2004
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer
C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ...
Jama 305 (18), 1873-1881, 2011
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235
PJA Eichhorn, M Gili, M Scaltriti, V Serra, M Guzman, W Nijkamp, ...
Cancer research 68 (22), 9221-9230, 2008
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor …
AU Buzdar, V Valero, NK Ibrahim, D Francis, KR Broglio, RL Theriault, ...
Clinical Cancer Research 13 (1), 228-233, 2007
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with …
S Kopetz, PM Hoff, JS Morris, RA Wolff, C Eng, KY Glover, R Adinin, ...
Journal of clinical oncology 28 (3), 453, 2010
Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer
S Ruggiero, J Gralow, RE Marx, AO Hoff, MM Schubert, JM Huryn, B Toth, ...
Journal of oncology practice 2 (1), 7-14, 2006
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2–positive, node-negative tumors 1 cm or smaller
AM Gonzalez-Angulo, JK Litton, KR Broglio, F Meric-Bernstam, R Rakkhit, ...
Journal of clinical oncology 27 (34), 5700, 2009
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
R Bruno, D Hille, A Riva, N Vivier, WW ten Bokkel Huinnink, ...
Journal of clinical oncology 16 (1), 187-196, 1998
The system can't perform the operation now. Try again later.
Articles 1–20